0001104659-15-008201.txt : 20150319 0001104659-15-008201.hdr.sgml : 20150319 20150210153617 ACCESSION NUMBER: 0001104659-15-008201 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bellerophon Therapeutics LLC CENTRAL INDEX KEY: 0001600132 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364771642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD, SUITE 301 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-574-4770 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD, SUITE 301 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: Bellerophon Therapeutics LLC DATE OF NAME CHANGE: 20140213 CORRESP 1 filename1.htm

 

Bellerophon Therapeutics LLC

53 Frontage Road, Suite 301

Hampton, New Jersey 08827

 

February 10, 2015

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:              Bellerophon Therapeutics LLC
Registration Statement on Form S-1
File No. 333-201474
Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Bellerophon Therapeutics LLC (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-201474), as amended (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern time on February 12, 2015, or as soon thereafter as practicable.

 

The Registrant hereby acknowledges that:

 

(a)                                 should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

(b)                                 the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

(c)                                  the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

[The remainder of this page is intentionally left blank.]

 


 

Very truly yours,

 

 

 

Bellerophon Therapeutics LLC

 

 

 

 

 

By:

/s/ Jonathan M. Peacock

 

Name:

Jonathan M. Peacock

 

Title:

President and Chief Executive Officer

 

 

[Signature Page to Acceleration Request]